体外液体培养联合低分子天然抑瘤物净化自体骨髓移植治疗AL

自体骨髓移植（ＡＢＭＴ）已广泛应用于急性白血病（ＡＬ）的治疗,并取得了可喜成果。但因骨髓中存在白血病残留细胞而使其成为移植后复发的重要原因之一,体外有效净化骨髓中残存的白血病细胞,减少复发成为人们关注的问题。我院１９９０年５月～１９９５年５月采用军事医学科学提供的长期骨髓液体培养（ＬＴＢＭＣ）联合低分子天然抑癌物（ＬＭＷＮＳ）体外净化法行ＡＢＭＴ治疗急性白血病１０例,报告如下：。１病例和方法１．１病例　１０例急性白血病均经骨髓形态、组化及免疫分型明确诊断。男７例,女３例。年龄１８～４６岁,平均年…     

非净化自体骨髓移植治疗3例急性白血病

急性白血病3例(急淋2例,急粒1例),均经化疗诱导达完全缓解后行非净化自体骨艇移植。骨髓采集于末次强化治疗2～3周进行,骨髓于体外不做其它净化处理。移植后均不再化疗。结果无1例发生严重副反应。1例在移植后4个月复发,余2例观察7个月和9个月无复发迹象。     

净化及非净化自体骨髓移植治疗白血病39例临床研究

报告自体骨髓移植治疗白血病３９例，其中非净化自体骨髓移植（ＡＢＭＴ）１４例，净化自体骨髓移植（ＰＡＢＭＴ）２５例。中位年龄２８岁（１０～４３岁）。ＡＭＬ２７例，ＡＬＬ１０例，ＣＭＬ２例。ＣＲ１３１例，ＣＲ２７例，ＮＲ１例。ＣＲ至移植时间中位数６．７个月（２～１９个月）。预处理方案：ＴＢＩ加Ａｒａ－ｃ、ＤＮＲ或ＶＰ１６。ＡＢＭＴ组及ＰＡＢＭＴ组３年无病生存（ＤＦＳ）率分别为６８．３２％及６７．５７％，复发率为３０．７６％及２６．８０％。但ＰＡＢＭＴ组ＡＭＬ患者３年ＤＦＳ率为８２．３５％及ＣＲ２期移７５％３年ＤＦＳ率为７５％，明显高于ＣＲ。期移植未净化者５０％。化疗组３年ＤＦＳ率为７．３８％及复发率７６．４％，两移植组疗效优于化疗组。     

自身骨髓移植在晚期恶性肿瘤治疗中的应用

本文报导我院1980～1991年6月因患各种晚期恶性肿瘤,主要是儿童恶性肿瘤患者50例,接受强化疗及自身骨髓移植治疗的临床小结。结果示(1)自身骨髓移植对治疗小儿恶性脑瘤、淋巴瘤、神经母细胞瘤等均有一定疗效,脑瘤组最明显;(2)脑瘤组在移植后需继续维持化疗3年左右,以防复发;(3)无论晚期淋巴瘤、神经母细胞瘤、急性白血病,在完全缓解期作移植,疗效好。(4)50例作自身移植者的结果提示自身骨髓移植对治疗晚期恶性肿瘤,是一种较安全、有效、值得采用的方法。     

骨髓间充质干细胞治疗脑梗死的研究进展

研究发现，骨髓间充质干细胞在适宜条件下可分化为神经元样细胞，并对脑梗死后神经功能缺损有明显的改善作用。文章就骨髓间充质干细胞的生物学特性、作用机制、存在的问题及其在脑梗死应用方面的研究进展做了综述。     

Comparison of Bone Marrow Involvement with Bone Marrow Biopsy and PET–CT and Evaluation of Any Effects on Survival in Patients Diagnosed with Hodgkin and Non-Hodgkin Lymphoma

We aimed to demonstrate whether PET–CT can replace bone marrow biopsy in detecting bone marrow involvement in subtypes of lymphoma. In addition, we aimed to also reveal whether there is a difference between the mean survival of patients with bone marrow involvement via PET–CT or biopsy. A total of 276 newly diagnosed lymphoma patients who underwent bone marrow biopsy and PET–CT prior to the treatment were scanned retrospectively. Bone marrow biopsy was used as the standard method to investigate the presence of bone marrow involvement in PET–CT. The relationship between bone marrow involvement and mean survival was compared using both methods. Out of the 276 patients, bone marrow involvement was detected with PET–CT and with biopsy, respectively in 56 patients (20.2%) and in 78 patients (28.2%). In terms of PET–CT’s accuracy with respect to revealing bone marrow involvement, the highest rates were achieved respectively in diffuse large B cell lymphoma (DLBCL) (87.4%) and Hodgkin lymphoma (HL) (77.7%). In both the PET–CT and bone marrow biopsy methods, Overall Survival (OS) was found to be significantly shorter in patients with involvement than in patients without involvement (P: 0.001). PET–CT may replace bone marrow (BM) biopsy in detecting the bone marrow involvement in aggressive lymphoma subtypes such as DLBCL and HL. The presence of BM involvement at the time of diagnosis in both PET–CT and BM biopsy is associated with poor prognosis, and OS is short in this group.     

采用1.068 g/ml分离液对犬骨髓间充质干细胞的分离纯化与体外培养方法的探讨

目的探讨更为可靠、纯净度高的犬骨髓间充质于细胞分离、培养方法。方法将犬骨髓抽取液分别以1．068g／ml及1．073g／ml分离液进行密度梯度离心，采用贴壁培养法获得骨髓间充质干细胞（MSCs）；以LG-DMEM加15％FBS培养；应用于细胞表面标志蛋白，多向诱导分化等方法进行细胞鉴定。结果采用1．068g／ml分离液可获得纯度较高的单核细胞，接种细胞生长良好，孵育24h即可见细胞贴壁生长，平均倍增周期为1d，细胞呈纺锤状，螺旋梳状排列。连续培育8代以上，未见细胞形态、增殖特性改变。MSCs表面标志SH2阳性，CD45阴性，可定向分化为心肌细胞、成骨细胞及脂肪细胞。结论采用1．068g／m1分离液能够较好地进行犬MSCs的体外分离、培养与扩增，分离得到的细胞具备MSCs的特性。     

Granulocytic Sarcoma Presenting with Severe Adenopathy (Cervical Lymph Nodes, Tonsils, and Adenoids) in a Child with Juvenile Myelomonocytic Leukemia and Successful Treatment with Allogeneic Bone Marrow Transplantation

The occurrence of adenopathy in patients with myelodysplastic syndrome-associated extramedullary myeloid cell tumors has rarely been reported. We describe a 7-year-old girl with juvenile myelomonocytic leukemia who showed the novel chromosomal abnormality t(9;12)(p22;q24.1) and who developed severe adenopathy of the cervical lymph nodes, tonsils, and adenoids that was manifested as granulocytic sarcoma. Following chemotherapy, the patient underwent a conditioning regimen of busulfan, cyclophosphamide, and total body irradiation followed by successful allogeneic bone marrow transplantation from her single HLA locus-mismatched mother at 6 months after her diagnosis. The patient continues to be well and in remission 3 years after stem cell transplantation.     

CFU-C Populations in Blood and Bone Marrow of Dogs after Lethal Irradiation and Allogeneic Transfusion with Cryopreserved Blood Mononuclear Cells

Colony forming units in agar (CFU-C) were assayed in both bone marrow and peripheral blood of dogs during haemopoietic recovery after lethal total-body irradiation (1200 R) and allogeneic transfusion of blood mononuclear cells (MNC) from histocompatible donors. MNC had been collected from the peripheral blood by continuous-flow centrifugation leucapheresis and cryopreserved at -196°C until transfusion. Two groups of dogs were studied. Group 1 dogs (n = 12) were given between 0.39 and 2.76 times 10⁹ MNC per kg body wt. Group 2 dogs (n = 14) were transfused with a similar number of MNC, ranging from 0.51 to 1.87 times 10⁹ per kg body wt., but in addition underwent immuno-suppressive therapy with methotrexate. In group 1 dogs, there was a rather good correlation between the number of CFU-C in the regenerating bone marrow and the recovery of the peripheral blood granulocyte values. The regeneration of the CFU-C population in the bone marrow of methotrexate-treated dogs showed a somewhat more heterogeneous picture than in dogs of group 1 and in dogs that, in a previous study, were transfused with autologous MNC. The minimum time interval required for the reconstitution of peripheral blood CFU-C to normal levels was 2–4 weeks but usually took from 4–14 weeks.     

Molecular and biochemical characterization of JAK3 deficiency in a patient with severe combined immunodeficiency over 20 years after bone marrow transplantation: implications for treatment

Summary. Severe combined immunodeficiency (SCID) comprises a heterogenous group of disorders that are fatal unless treated by bone marrow transplantation (BMT). The most common form of SCID (T^?B⁺ SCID) is due to mutations of either the common gamma chain (γc) or of γc-coupled JAK3 kinase. We report an unusual JAK3 defect in a female who was successfully treated >20 years ago with a BMT using her HLA-identical father as the donor. Persistence of genetically and biochemically defective autologous B cells, associated with reconstitution of cellular and humoral immunity, suggests that integrity of the γc-JAK3 signalling pathway is not strictly required for immunoglobulin production.